Announcement date
19 December 2024
Link to announcement
https://www.health.gov.au/resources/publications/first-pharmaceutical-wholesaler-agreement-1pwa?language=en
Problem being addressed
Pharmaceutical wholesalers (wholesalers) have an important role in Australia’s medicines supply chain. Wholesalers are the link between pharmaceutical manufacturers and the community pharmacy network. Stock is imported into Australia by pharmaceutical manufacturers and stored in bulk third-party logistic facilities. Wholesalers procure this stock, warehouse it in accordance with stocking requirements, and distribute directly to community pharmacies on request. The efficiency and continued viability of this key link in the supply chain is crucial to support patient access to medicines.
This Impact Analysis (IA) was prepared to support negotiation of an agreement between the Commonwealth and the National Pharmaceutical Services Association (NPSA), known as the Pharmaceutical Wholesaler Agreement (PWA). The purpose of the PWA is to reform Pharmaceutical Benefits Scheme (PBS) wholesaler arrangements to support a stronger and more sustainable pharmaceutical sector that continues to support Australian patients in-line with the National Medicines Policy (NMP).
Proposal
The IA considered three options in negotiating the PWA:
- Option 1: Do not establish a PWA (status quo). Maintain existing wholesaler arrangements negotiated through the 7th and 8th Community Pharmacy Agreement (CPA)
- Option 2: Establish PWA and accept NPSA proposal in-full
- Option 3A: Establish PWA, implement structural policy reforms (including Community Service Obligation (CSO) demand-driven reforms), and align remuneration with wholesaler costs
- Option 3B: Establish PWA, implement structural policy reforms (not including CSO demand-driven reforms), and align remuneration with wholesaler costs.
Option 3B as preferred option in the IA as it represents the highest net benefit and does not present a regulatory burden significantly higher than other comparable options.
Assessed Impact Analysis outcome
Good practice
Assessment comments
The IA addresses the seven IA questions and follows an appropriate policy development process commensurate with the significance of the problem and magnitude of the proposed intervention. To be considered 'exemplary' as per the Australian Government Guide to Policy Impact Analysis, the IA would have benefited from a more detailed discussion of the costs and benefits to the various stakeholder groups in the Multi-Criteria Analysis.
The publication of the IA was delayed due to the time needed for the Department of Health, Disability and Ageing (then the Department of Health and Aged Care) to establish and redact commercially sensitive material and information from the IA for publication.
Regulatory burden
The Department of Health, Disability and Ageing estimates the preferred option will result in a regulatory burden over five years of $17.04 million on average per year.